Bennett Lawrence Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Bennett Lawrence Management’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-65,835	Closed	-$3.35M	–	89
2014 Q4	$3.35M	Sell	65,835 -44,680	-40%	-$2M	0.9%	45
2014 Q3	$4.37M	Sell	110,515 -7,930	-7%	-$316K	0.99%	43
2014 Q2	$5.1M	Buy	118,445 +84,440	+248%	+$3.22M	0.9%	44
2014 Q1	$1.36M	Buy	+34,005	New	+$1.24M	0.2%	73

Other funds holding ENTA

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

ACM

Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

MVM

McClain Value Management New Canaan, Connecticut $50.9M AUM 16.06% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bennett Lawrence Management's ENTA Position: Q1 2015 in Review

Bennett Lawrence Management sold out of Enanta Pharmaceuticals (ENTA) in Q1 2015, closing a stake of 65,835 shares — an estimated $3.35M sold.

Bennett Lawrence Management first reported a position in ENTA in Q1 2014 and held it in 4 quarters. The position peaked at $5.1M in Q2 2014. 117 funds tracked by Wall St. Rank hold ENTA as of Q1 2015.

Bennett Lawrence Management reported no remaining Enanta Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
Bennett Lawrence Management sold 65,835 Enanta Pharmaceuticals shares in Q1 2015, an estimated $3.35M.
Bennett Lawrence Management first reported a position in Enanta Pharmaceuticals in Q1 2014 and held it in 4 quarters.
Bennett Lawrence Management's Enanta Pharmaceuticals position peaked at $5.1M in Q2 2014.
117 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2015.

Based on Bennett Lawrence Management's 13F filing for Q1 2015, filed 20 Apr 2015.